A detailed history of Smith, Moore & Co. transactions in Novo Nordisk A S stock. As of the latest transaction made, Smith, Moore & Co. holds 2,761 shares of NVO stock, worth $298,215. This represents 0.03% of its overall portfolio holdings.

Number of Shares
2,761
Previous 4,099 32.64%
Holding current value
$298,215
Previous $585,000 43.93%
% of portfolio
0.03%
Previous 0.06%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$119.07 - $145.42 $159,315 - $194,571
-1,338 Reduced 32.64%
2,761 $328,000
Q2 2024

Aug 14, 2024

BUY
$122.71 - $146.91 $22,578 - $27,031
184 Added 4.7%
4,099 $585,000
Q1 2024

May 10, 2024

BUY
$102.11 - $135.92 $21,953 - $29,222
215 Added 5.81%
3,915 $502,000
Q4 2023

Feb 13, 2024

BUY
$87.78 - $105.45 $61,446 - $73,815
700 Added 23.33%
3,700 $382,000
Q3 2023

Nov 14, 2023

BUY
$90.94 - $199.54 $272,820 - $598,620
3,000 New
3,000 $272,000

Others Institutions Holding NVO

About NOVO NORDISK A S


  • Ticker NVO
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 2,257,289,984
  • Market Cap $244B
  • Description
  • Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabeti...
More about NVO
Track This Portfolio

Track Smith, Moore & Co. Portfolio

Follow Smith, Moore & Co. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Smith, Moore & Co., based on Form 13F filings with the SEC.

News

Stay updated on Smith, Moore & Co. with notifications on news.